1. Scrip
  2. >>Business

GSK Looks To Long-Acting Therapy To Restore Lead In HIV

Targeting HIV Cure By 2030

 
• By Andrew McConaghie

GSK looks to Cabenuva to get ahead in the long-acting HIV therapy and PrEP market, but Gilead will not relinquish its lead easily.

GSK syringes
Cabenuva has got off to a slow start thanks to the pandemic, but GSK hope it can become a multi-billion dollar product • Source: Alamy

GlaxoSmithKline is looking to regain market share in HIV with its long-acting antiretroviral regimens, an area where it has taken the lead on its rivals.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip